Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CVM NASDAQ:ELEV NASDAQ:LIAN NASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVMCEL-SCI$9.45+15.5%$3.59$1.98▼$39.30$50.28M0.3380,418 shs521,184 shsELEVElevation Oncology$0.37$0.36$0.22▼$3.09$21.62M1.481.18 million shsN/ALIANLianBio$0.05$0.30$0.27▼$4.99$5.87M0.231.04 million shs3 shsLSTALisata Therapeutics$2.49+0.2%$2.62$1.87▼$4.20$21.37M1.0355,648 shs2,477 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVMCEL-SCI+15.53%+15.24%+275.00%+25.50%-72.25%ELEVElevation Oncology0.00%0.00%-3.62%+4.29%-86.12%LIANLianBio0.00%+8.92%-87.26%-73.75%-82.76%LSTALisata Therapeutics+0.20%-7.62%-8.97%+3.11%-22.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVMCEL-SCI1.1236 of 5 stars0.02.00.00.03.91.70.6ELEVElevation Oncology2.6793 of 5 stars3.05.00.00.00.01.70.6LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/ALSTALisata Therapeutics2.314 of 5 stars3.54.00.00.00.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVMCEL-SCI 0.00N/AN/AN/AELEVElevation Oncology 2.00Hold$3.39827.59% UpsideLIANLianBio 0.00N/AN/AN/ALSTALisata Therapeutics 3.00Buy$23.50845.67% UpsideCurrent Analyst Ratings BreakdownLatest LIAN, CVM, LSTA, and ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025LSTALisata TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $32.006/10/2025ELEVElevation OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/10/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Neutral6/9/2025ELEVElevation OncologyTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/9/2025ELEVElevation OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVMCEL-SCIN/AN/AN/AN/A$0.15 per shareN/AELEVElevation OncologyN/AN/AN/AN/A$1.02 per shareN/ALIANLianBioN/AN/AN/AN/A$2.71 per shareN/ALSTALisata Therapeutics$1M21.41N/AN/A$3.49 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVMCEL-SCI-$26.92M-$12.61N/AN/AN/AN/A-238.05%-104.65%N/AELEVElevation Oncology-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%8/5/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/ALSTALisata Therapeutics-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/7/2025 (Estimated)Latest LIAN, CVM, LSTA, and ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025LSTALisata Therapeutics-$0.64N/AN/AN/AN/AN/A8/5/2025Q2 2025ELEVElevation Oncology-$0.26N/AN/AN/AN/AN/A5/15/2025Q1 2025ELEVElevation Oncology-$0.20-$0.24-$0.04-$0.24N/AN/A5/8/2025Q1 2025LSTALisata Therapeutics-$0.53-$0.55-$0.02-$0.55N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVMCEL-SCIN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVMCEL-SCI0.661.071.09ELEVElevation Oncology0.6719.4019.40LIANLianBioN/A10.0610.06LSTALisata TherapeuticsN/A7.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVMCEL-SCI12.08%ELEVElevation Oncology83.70%LIANLianBio74.85%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipCVMCEL-SCI9.93%ELEVElevation Oncology8.10%LIANLianBio7.59%LSTALisata Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVMCEL-SCI435.32 million64.67 millionOptionableELEVElevation Oncology4059.22 million54.43 millionOptionableLIANLianBio110108.06 million99.86 millionNot OptionableLSTALisata Therapeutics308.62 million7.79 millionNot OptionableLIAN, CVM, LSTA, and ELEV HeadlinesRecent News About These CompaniesLisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025July 31 at 8:00 AM | globenewswire.comLisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary resultsJuly 17, 2025 | proactiveinvestors.comLisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data UpdateJuly 17, 2025 | globenewswire.comLisata Therapeutics, Inc.: Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for CertepetideJuly 15, 2025 | finanznachrichten.deLisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for CertepetideJuly 15, 2025 | finance.yahoo.comLisata Therapeutics expands IP with key patent covering certepetide's chemical structure and usesJuly 15, 2025 | proactiveinvestors.comLisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for CertepetideJuly 15, 2025 | globenewswire.comLisata Therapeutics and GATC advance AI-driven opioid use disorder therapy - ICYMIJuly 12, 2025 | proactiveinvestors.comLisata Therapeutics, Inc. (LSTA) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comLisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancerJune 26, 2025 | proactiveinvestors.comLisata and GATC to use AI for new opioid use disorder drugJune 18, 2025 | thepharmaletter.comTLisata Therapeutics to lead development of opioid use disorder drug under expanded allianceJune 17, 2025 | proactiveinvestors.comLisata Therapeutics, Inc.: Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17, 2025 | finanznachrichten.deLisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC HealthJune 17, 2025 | proactiveinvestors.comLisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17, 2025 | globenewswire.comLisata Therapeutics to Present at the 2025 BIO International ConventionJune 11, 2025 | globenewswire.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Call TranscriptMay 9, 2025 | msn.comLisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ...May 9, 2025 | finance.yahoo.comLisata Therapeutics’ Earnings Call Highlights ProgressMay 9, 2025 | tipranks.comLisata Therapeutics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIAN, CVM, LSTA, and ELEV Company DescriptionsCEL-SCI NYSE:CVM$9.45 +1.27 (+15.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.29 -0.16 (-1.69%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Elevation Oncology NASDAQ:ELEV$0.36 0.00 (0.00%) As of 07/23/2025Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.LianBio NASDAQ:LIAN$0.05 0.00 (0.00%) As of 08/1/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Lisata Therapeutics NASDAQ:LSTA$2.48 +0.01 (+0.20%) Closing price 08/1/2025 03:54 PM EasternExtended Trading$2.50 +0.02 (+0.60%) As of 08/1/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.